Please Wait
Applying Filters...
menu
    • menu
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    An Enquiry

    Evonik Health Care is the innovation hub for leading life science companies

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    An Enquiry

    Menu

    Gadolinium

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    $ API Ref.Price (USD/KG) : 1,499Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Zenas Biopharma Presents Phase 2 Obexelimab Results In Relapsing
    Zenas Biopharma Presents Phase 2 Obexelimab Results In Relapsing

    09 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/09/3234414/0/en/Zenas-BioPharma-Announces-Late-Breaking-Platform-Presentation-of-Results-from-Phase-2-MoonStone-Trial-of-Obexelimab-in-Relapsing-Multiple-Sclerosis-at-ACTRIMS-Forum-2026.html

    GLOBENEWSWIRE
    09 Feb 2026
    Share Share
    EU Approves Guerbet's Half-Dose Elucirem for Kids
    EU Approves Guerbet's Half-Dose Elucirem for Kids

    27 Jan 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/new-indication-in-children-from-birth-for-guerbets-half-dose-gbca-elucirem-gadopiclenol-approved-by-european-commission-302671258.html

    PR NEWSWIRE
    27 Jan 2026
    Share Share
    Hyperfine Enrolls First Patient To Expand Swoop System Use
    Hyperfine Enrolls First Patient To Expand Swoop System Use

    15 Jan 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260115207956/en/Hyperfine-Announces-Enrollment-of-First-Patient-in-Study-to-Expand-Intended-Use-of-the-Swoop-System-with-Contrast-Agents

    BUSINESSWIRE
    15 Jan 2026
    Share Share
    Bayer's Gadoquatrane Meets Key Endpoints in Kids' Study at RSNA25
    Bayer's Gadoquatrane Meets Key Endpoints in Kids' Study at RSNA25

    03 Dec 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251203017985/en/RSNA25-Pediatric-Study-for-Bayers-Investigational-MRI-Contrast-Agent-Gadoquatrane-Meets-Primary-and-Secondary-Endpoints

    BUSINESSWIRE
    03 Dec 2025
    Share Share
    Zenas Autoimmune Drug Prompts 95% Drop In Lesions In MS Study
    Zenas Autoimmune Drug Prompts 95% Drop In Lesions In MS Study

    27 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/27/3174445/0/en/Zenas-BioPharma-Announces-Positive-Results-from-Phase-2-MoonStone-Trial-of-Obexelimab-in-Relapsing-Multiple-Sclerosis.html

    GLOBENEWSWIRE
    27 Oct 2025
    Share Share
    Bayer Applies for EU Approval of Gadoquatrane MRI Agent
    Bayer Applies for EU Approval of Gadoquatrane MRI Agent

    11 Jul 2025

    // INDPHARMAPOST

    https://www.indianpharmapost.com/news/bayer-submits-eu-application-for-gadoquatrane-mri-contrast-agent-17388

    INDPHARMAPOST
    11 Jul 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.